Form 4: Rani Therapeutics: 10% Owner Sells 5.9M Shares

South Cone Investments, a 10% owner and director of Rani Therapeutics Holdings, Inc., reported the sale of 5,923,000 shares of Class A Common Stock over two days.

Summary

• South Cone Investments Limited Partnership, a 10% owner and director of Rani Therapeutics Holdings, Inc. (RANI), reported the sale of 5,923,000 shares of Class A Common Stock.
• The transactions occurred on October 20, 2025, and October 21, 2025, and were made pursuant to a Rule 10b5-1 trading plan.
• On October 20, 2025, 1,923,000 shares were sold at a weighted average price of $2.4115 per share, with prices ranging from $2.25 to $2.61.
• On October 21, 2025, an additional 4,000,000 shares were sold at a weighted average price of $2.7685 per share, with prices ranging from $2.50 to $3.09.
• Following these transactions, South Cone Investments Limited Partnership indirectly holds 2,379,194 shares through South Lake One LLC.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the substantial insider selling by a 10% owner and director, which typically signals a lack of confidence or a strategic exit, potentially impacting investor sentiment negatively.

Positives

• None directly identified in this filing, which reports significant insider selling.

Negatives

• Significant insider selling by a 10% owner and director, totaling 5,923,000 shares, which can signal a lack of confidence in the company's future prospects.
• The sales occurred at prices ranging from $2.25 to $3.09, potentially indicating a belief that the current stock price is a favorable exit point for the insider.

Risks

• Negative market perception due to substantial insider selling by a key stakeholder, potentially leading to downward pressure on the stock price.
• Reduced alignment of interests between the reporting person and other shareholders following the significant reduction in holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Rani Therapeutics Holdings, Inc. It solely reports insider trading activity.

Industry Context

This filing reports an insider transaction and does not provide specific details to analyze it within broader industry trends or against competitors. However, significant insider selling in the biotechnology or pharmaceutical sector can sometimes be viewed with caution, especially if the company is in a critical development phase.

Related Party Transactions

• South Cone Investments Limited Partnership directly owns 100% of the issued and outstanding membership interest of South Lake One LLC, through which the reported shares are indirectly held.

Stakeholder Impact

• Shareholders may interpret the significant insider selling as a negative indicator, potentially leading to decreased investor confidence and downward pressure on the stock price.

Next Steps

• The reporting person undertakes to provide full information regarding the number of shares purchased at each separate price within the reported ranges upon request to Rani Therapeutics Holdings, Inc., any security holder, or the SEC staff.

Key Dates

Recommendation

While significant insider selling by a 10% owner and director is a negative signal, a 'hold' recommendation is appropriate without further context on the company's fundamentals, strategic direction, or the insider's specific reasons for selling (e.g., diversification, liquidity needs). Investors should monitor future filings and company performance closely.

Keywords

Rani Therapeutics, RANI, Insider Selling, Form 4, South Cone Investments, Stock Sale, 10% Owner, Director Transaction, Equity Disposal, Rule 10b5-1